Clinical trial
Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in…
NCT00040534 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00040534 |
|---|---|
| Title | Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | Farnesyl Protein Transferase Inhibitor |
| Enrollment | 22 |
| Start date | Jan 1, 2001 |
| Primary completion | Jul 1, 2004 |
| Completion | Jul 1, 2004 |
| First posted | Jul 1, 2002 |
| Last update posted | Feb 16, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: